Global Genome Engineering Market Market Companies
- Thermo Fisher Scientific Inc.
- CRISPR Therapeutics AG
- Intellia Therapeutics, Engineering
- Editas Medicine, Inc.
- Sangamo Therapeutics, Inc.
- Bluebird Bio, Inc.
- Cellectis S.A.
- Merck Group.
- Vigene Biosciences
- Transposagen Biopharmaceuticals
Recent News:
- In March 2024, Carolina Biological Supply Company partnered with the ChristianaCare Institute for Gene Editing to develop a proprietary CRISPR in a Box educational kit for grades 9-12 and higher education, providing hands-on exercises to teach CRISPR techniques.
- In January 2024, Danaher Corporation partnered with the Innovative Genomics Institute (IGI). The collaboration aims to develop CRISPR-based therapies for rare genetic diseases, leveraging Danaher’s diverse technological resources and IGI’s academic expertise.
- In November 2023, Cellectis and AstraZeneca entered into a collaboration agreement to accelerate the development of innovative therapies in oncology and immunology.
- In July 2023, Sangamo Therapeutics and Chroma Medicine partnered to develop epigenetic drugs using Sangamo's zinc finger proteins (ZFPs). Chroma will evaluate ZFPs for specific targets outside the central nervous system, potentially licensing them for development and commercialization.
- In May 2023, a research program at the Lewis Katz School of Medicine at the University of Nebraska Medical Center reported successful treatment of HIV infection in animals using CRISPR. In December 2022, a CRO called Crown Bioscience, Inc. partnered with ERS Genomics Limited to access ERS’ CRISPR/Cas9 patent portfolio and increase its market presence in the gene editing space.